Ning Li

机构：The Ohio State University Wexner Medical Center · ORCID：0000-0001-6750-4308

发表论文 146 篇 · 总被引 3572 次 · h-index 29

代表论文

• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 88)
• Distinct chemical degradation pathways of AAV1 and AAV8 under thermal stress conditions revealed by analytical anion exchange chromatography and LC-MS-based peptide mapping (2024 · Journal of Pharmaceutical and Biomedical Analysis · 被引 15)
• Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production (2024 · Chemico-Biological Interactions · 被引 14)
• The impact of early cranioplasty on neurological function, stress response, and cognitive function in traumatic brain injury (2024 · Medicine · 被引 13)
• Characterization of adeno-associated virus capsid proteins using denaturing size-exclusion chromatography coupled with mass spectrometry (2024 · Journal of Pharmaceutical and Biomedical Analysis · 被引 9)
• Development of a Flow Through-Based Limited Digestion Approach for High-Throughput and High-Sequence Coverage Mapping of Therapeutic mRNAs (2024 · Analytical Chemistry · 被引 9)